QuidelOrtho Corp(QDEL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -15.41 | Insider Own | 0.9% | Shs Outstand | 68.3M | Perf Week | 2.08% |
| Market Cap | 0.94B | Forward P/E | 9.64 | EPS next Y | 85.11% | Insider Trans | - | Shs Float | 68.0M | Perf Month | 30.55% |
| Enterprise Value | 3.90B | PEG | - | EPS next Q | 0.2 | Inst Own | 116.93% | Short Float | 19.12% | Perf Quarter | -17.95% |
| Income | -1.05B | P/S | 0.35 | EPS this Y | -63.61% | Inst Trans | -10.53% | Short Ratio | 7.38 | Perf Half Y | 11.87% |
| Sales | 2.67B | P/B | 0.53 | EPS next 5Y | -4.59% | ROA | -17.34% | Short Interest | 12.99M | Perf YTD | -51.82% |
| Book/sh | 25.99 | P/C | 7.65 | EPS past 3/5Y | - | ROE | -45.91% | 52W High | -61.32% ($35.58) | Perf Year | -50.75% |
| Cash/sh | 1.8 | P/FCF | - | Sales past 3/5Y | -5.81% 10.42% | ROIC | -23.49% | 52W Low | 38.71% ($9.92) | Perf 3Y | -77.44% |
| Dividend Est. | - | EV/EBITDA | 9.21 | EPS Y/Y TTM | -135.75% | Gross Margin | 37.68% | Volatility(W/M) | 9.25% 8.38% | Perf 5Y | -89.64% |
| Dividend TTM | - | EV/Sales | 1.46 | Sales Y/Y TTM | -2.57% | Oper. Margin | -1.16% | ATR (14) | 0.99 | Perf 10Y | -29.25% |
| Dividend Ex-Date | - | Quick Ratio | 0.76 | EPS Q/Q | 63.94% | Profit Margin | -39.21% | RSI (14) | 56.02 | Recom | 3.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.39 | Sales Q/Q | 2.45% | SMA20 | 3.83% ($13.25) | Beta | 0.83 | Target Price | $14.67 |
| Payout | - | Debt/Eq | 1.73 | Earnings | 2026/11/3 | SMA50 | 7.59% ($12.79) | Rel Volume | 0.86 | Prev Close | $14.01 |
| Employees | 6500 | LT Debt/Eq | 1.51 | EPS/Sales Surpr. | 366.39% 1.97% | SMA200 | -15.91% ($16.36) | Avg Volume(3M) | 1.76M | Price | $13.76 |
| IPO | 1991/2/1 | Option/Short | Yes/Yes | Trades | 15542 | Volume | 1,508,078 | Change | -1.78% |
🔬 QuidelOrtho (QDEL) is a global in vitro diagnostics company covering immunodiagnostics, molecular diagnostics, clinical chemistry, and transfusion medicine. It supplies a wide range of clinical laboratory diagnostic instruments, rapid antigen tests, and transfusion medicine solutions, with its Labs business serving as the core revenue driver. The company operates both respiratory disease testing and non-respiratory diagnostics, offering a portfolio that spans the full diagnostics landscape.
Over the past 1 year, on the lower side
61% below its 1-year high.
Traded about as much as usual. That is 86% of its average volume.
Next earnings report: November 3
5 days to go.
QDEL has weak earning power
Of every $100 in sales, $1.16 is lost.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -63.6% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $35. Peers typically go for $343. Compared with its own 1-year average, it is 677% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -89.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 116.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #46 of 142 in the industry
Based on market cap of $944M.
FAQ
What kind of company is QDEL?
QDEL belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of QDEL?
The market cap of QDEL is approximately $944M, ranking 2,632 within its sector.
What is the 52-week high and low for QDEL?
QDEL has recorded a 52-week high of $35.58 and a low of $9.92.
